January 11, 2017
Eli Lilly, Merck expand collaboration against cancer
Eli Lilly and Merck have expand an existing immuno-oncology collaboration through a subsidiary to add a new study of Lilly’s…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 11, 2017
Evgen Pharma gets positive DSMB review of SAS trial
Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.
January 11, 2017
ValiRx encouraged by initial trials of cancer drug study, expands to more sites
A clinical stage biotechnology company, ValiRX, said on Wednesday that its VAL201 personalised Phase l/II prostate cancer study brought positive results.
January 11, 2017
Premaitha closes deal on Yourgene acquisition
Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
January 11, 2017
Director Jonathan Freeman’s Dealings
Futura Medical, the innovative healthcare company focused on advanced transdermal technology has been notified that on 10 January 2017, Jonathan…
January 11, 2017
UPDATE: Omega starts selling malaria tests in India
Food allergy focused medical diagnostic company Omega has gotten ISO certification for the Quality Management System for its Asian subsidiary in India, and it started with the domestic sales of its products.
January 11, 2017
Genfit: half-year report of liquidity contract with CIC
GENFIT, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that affect the liver…
January 11, 2017
FDA calls for more patient enrollments
The U.S. Food and Drug Administration (FDA) has noticed that lately for certain reason, there are fewer number of people willing to participate in clinical trials for different medications. Therefore, it has decided to encourage patients to take a part in helping researching companies to develop new drugs.
January 10, 2017
Japanese Takeda in a $5.2 billion acquisition deal with USA-based Ariad
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.
January 10, 2017
Regeneron CEO says Amgen not putting patients first in patent dispute
Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.